JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LaFleur, D. W.
Right arrow Articles by Sharifi, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LaFleur, D. W.
Right arrow Articles by Sharifi, B. G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 272, Number 52, Issue of December 26, 1997 pp. 32798-32803

Aortic Smooth Muscle Cells Interact with Tenascin-C through Its Fibrinogen-like Domain*

(Received for publication, August 11, 1997, and in revised form, October 8, 1997)

David W. LaFleur , Julie Chiang , James A. Fagin , Stephen M. Schwartz Dagger , Prediman K. Shah , Kurt Wallner , James S. Forrester and Behrooz G. Sharifi §

From the Atherosclerosis Research Center, Division of Cardiology, Burns and Allen Research Institute, Cedar-Sinai Medical Center, University of California School of Medicine, Los Angeles, California 90048 and Dagger  Division of Pathology, University of Washington, Seattle, Washington 98195

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

The extracellular matrix protein tenascin-C is a multidomain protein that regulates cell adhesion. We used two different smooth muscle cell subtypes derived from adult and newborn rat aorta to investigate the interaction of tenascin-C or its various domains with these cells using an adhesion assay. Newborn cells were three times more adherent to tenascin-C than adult cells. Tenascin C-adhering cells remained round, whereas they spread rapidly on a fibronectin substrate. Adhesion assays showed the interaction between tenascin-C and newborn cells to be predominantly RGD-independent. Mg2+ increased newborn cell adhesion to tenascin-C in a concentration-dependent manner, whereas Ca2+ had no effect. To analyze the structure-function relationships of different domains of tenascin-C, we used recombinant full-length fibronectin-like and fibrinogen-like domains and various subdomains corresponding to the alternatively spliced regions of tenascin-C. The cells adhered to the fibrinogen-like domain but not to the fibronectin-like domain or its subdomains. As with the intact tenascin-C molecule, adherent cells remained round, and the Mg2+, but not Ca2+, promoted this interaction. The interaction of cells with the fibrinogen-like region was further mapped to a 30-amino acid peptide located near the carboxyl-terminal part of the tenascin-C molecule. The same 30-amino acid peptide was active in promoting cell migration. Our results provide a basis for understanding the mechanism of interaction of tenascin-C with smooth muscle cells and a framework for isolating membrane binding sites that mediate the cellular responses to this molecule.

INTRODUCTION

Tenascin-C is an oligomeric glycoprotein composed of multiple domains that has been implicated in cell migration (1-7). Human, mouse, and chicken tenascin-C contain a cysteine-rich segment at their amino termini through which the six tenascin-C monomers link into a hexamer. This segment is followed by epidermal growth factor-like repeats, fibronectin-type III repeats (FN-L),1 and a globular carboxyl terminus homologous to fibrinogen (Fbg-L) (8). These domains mediate the interaction between the tenascin-C molecule and cells. For example, endothelial cells interact with tenascin-C through its fibrinogen-like domain (9), whereas the FN-L domain of tenascin-C mediates interaction with fibroblasts (10). The specific domain of tenascin-C that mediates its interaction with SMCs is unknown.

We have previously demonstrated that chemotactic factors involved in the remodeling of vascular tissues including platelet-derived growth factor BB and angiotensin II markedly induce tenascin-C gene expression in SMCs (11, 12). To gain insight into the molecular mechanism of tenascin-C-SMC interactions, we mapped the active site of tenascin-C. Using recombinant proteins corresponding to the Fbg-L and FN-L domains of tenascin-C, we demonstrated that the Fbg-L domain, but not FN-L domain, is the active domain. We further mapped the active site of the Fbg-L domain and demonstrated that the activity of the Fbg-L domain can be duplicated by a 30-amino acid peptide.

EXPERIMENTAL PROCEDURES

Materials

Tenascin C was purified from conditioned media of baby hamster kidney cells overexpressing tenascin-C, as described (10). The recombinant proteins corresponding to the full-length Fbg-L and FN-L domains were expressed and purified from the bacteria BL-21 Escherichia coli provided by Dr. Harold Erickson (Duke University). Dr. John Peters (Cedar-Sinai Medical Center) kindly provided the recombinant fibronectin type III unit 10. Prestained protein standards were from Bio-Rad. Other chemicals were of reagent grade quality and obtained from Sigma.

Cell Culture

Adult aortic SMCs were cultured as described (12). Newborn (9 days old) aortic SMCs were obtained from Dr. Stephen M. Schwartz (University of Washington) and cultured (13). Briefly, rat aortic SMCs were isolated by enzymatic digestion of rat (Sprague-Dawley, 2 months old, 270 g) aorta. Cells were grown in DMEM/F-12 medium (Life Technologies, Inc.) supplemented with 10% fetal bovine serum (Life Technologies, Inc.). After reaching confluence, cells (between the third and sixth passages) were used for adhesion studies.

Adhesion Assay

Microtiter plates (Falcon; Becton Dickinson, Oxnard, CA) were coated with the respective substrate for 1 h at 37 °C. Nonspecific sites were blocked with 1 mg/ml BSA in phosphate-buffered saline. Subconfluent cells exhibited higher adhesion activity than confluent cultured cells; therefore, cells were split and plated at half confluence the day before the assay. SMC subtypes were detached by trypsin/EDTA, washed once in DMEM/F-12 medium, 2.5 mg/ml BSA, and 1 mg/ml trypsin inhibitor (adhesion buffer) and plated at 4 × 104 cells/well. After incubation for 60 min at 37 °C, nonadherent cells were removed with gentle washing with phosphate-buffered saline. The number of attached cells were quantified by staining cells with 0.2% crystal violet in 20% methanol, lysing with 1% SDS, and measuring the absorbance at 550 nm (14).

To determine the concentration for the adhesion assays, microtiter plates were coated with increasing concentrations (1-100 µg/ml) of substrates, and the number of adherent cells was quantified. Adhesion of cells to tenascin-C reached saturation levels at coating concentrations of 10 µg/ml (not shown); therefore, all the subsequent adhesion assays were performed by coating the wells with 10 µg/ml substrate.

Expression of Recombinant FN-L Subdomains

The PET expression system was used to express the recombinant FN-L subdomains (10). The primers were targeted to the exact boundaries of the alternatively spliced fibronectin type III repeats corresponding to each isoform of tenascin-C. A BamHI site together with the NdeI site provided for unidirectional ligation downstream from the T7 promoter in the expression vector pET11a (Novagen, Madison, WI). The cloned subunits were resequenced to ensure that no errors had been introduced during the cloning process. The resultant construct was transformed into the E. coli expression host BL21 (DE3) (Novagen). Clonal cultures were grown in LB medium containing 50 µg/ml carbenicillin and induced with isopropyl-1-thio-beta -D-galactopyranoside for 3 h. Polyclonal antibodies to tenascin-C were used to identify the recombinant proteins. To further assess the integrity of the recombinant proteins, their amino acid composition and partial amino acid sequences were determined (UCLA amino acid sequencing core facility). Both corresponded exactly to the predicted values (not shown).

Peptide Synthesis

Peptides corresponding to the full-length Fbg-L domain were synthesized in the UCLA peptide synthesis core facility. The peptides were synthesized using Fmoc (N-(9-fluorenyl)methoxycarbonyl) strategies on an Advanced Chem Tech multiple synthesizer model 396, cleaved at room temperature (cleavage mixture: 90% trifluoroacetate, 5% thioanisol, 3% ethanedithiol, 2% anisole), purified by reverse phase high performance liquid chromatography, and characterized by mass spectral analysis (at the UCLA mass spectroscopy facility) and high performance capillary electrophoresis (Beckman 2200 HPCE). The core facility was unable to synthesize peptides II and VII, presumably due to the formation of a strong secondary structure that prevented elongation of the peptide chain.

Migration Assay

Cell migration was measured by a modification of the Boyden's chamber method using microchemotaxis chambers (Neuro Probe Inc). Polycarbonate filters were coated with 10 µg/ml concentrations of substrates overnight at 4 °C. Newborn rat SMCs were suspended at a concentration of 105 cells/ml in serum-free DMEM supplemented with 1 mg/ml BSA. A volume of 50 µl of cell suspension was placed in the upper chamber, and 30 µl of 10% bovine calf serum in DMEM was placed in the lower chamber. In some experiments, cells were suspended in DMEM supplemented with 0.1 µM Fbg-L or 1 µM peptide VIII before addition to the upper chamber. The chamber was incubated at 37 °C under 5% CO2 in air for 4 h. The filter was removed, and the cells on the upper side of the filter were scraped off. The SMCs that had migrated to the lower side of the filter were fixed in methanol, stained with Diff-Quick staining solution (Baxter), and counted under a microscope.

RESULTS

Effect of Tenascin C on Cell Adhesion in Different SMC Subtypes

Interaction between aortic SMCs and tenascin-C was assessed by adhesion assay. Adult rat aortic SMCs avidly adhered to wells coated with fibronectin and vitronectin (Fig. 1). By contrast, adhesion to tenascin-C was 3-4 times lower than attachment to the adhesive proteins. Tenascin C-adherent cells remained round, whereas spreading and flattening followed attachment to fibronectin and vitronectin (not shown). The reduced adhesion of adult SMCs with tenascin-C indicates that either complete binding equilibrium did not occur at 60 min or that adult SMCs have diminished the ability to interact with tenascin-C. We found that the interaction reached equilibrium levels at 60 min (not shown); therefore, the reduced SMC-tenascin-C interaction most likely reflects a lower adhesive capacity of adult SMCs for tenascin-C.

Fig. 1. Adhesion of SMCs to the matrix proteins. 96-well plates were coated with solutions containing intact fibronectin (striped), vitronectin (gray), or tenascin-C (black) and incubated with either adult or newborn aortic SMCs. Adhesion is measured by determining absorbance of attached cells after staining with crystal violet. Values shown are from a representative experiment in which triplicates are plotted as mean ± S.E. Unshaded bars, BSA.

[View Larger Version of this Image (26K GIF file)]

Since tenascin-C is prominently expressed during embryogenesis (8, 15), we postulated that SMCs derived from newborn arteries might express a higher number of tenascin-C receptors. To explore this possibility, we examined the adhesion of cultured newborn SMCs to tenascin-C (Fig. 1). The levels of adhesion of newborn SMCs to tenascin-C were 3-4 times higher than adult cells and were comparable to the attachment levels observed with fibronectin (Fig. 1).

The Role of RGD Motif in Cell Binding

It has been shown that the interaction of some cells with tenascin-C is mediated by the RGD motif (9, 16). Therefore, we determined the role of RGD in the interaction between tenascin-C and SMCs by an adhesion assay. The specificity of the adhesion was determined by coating the wells with the recombinant 10th-type III repeat of fibronectin (17). As shown in Fig. 2, GRGDS peptide inhibited the attachment of newborn SMCs to the recombinant fibronectin fragment, and complete inhibition was observed at 0.1 mg/ml. Attachment of SMCs to tenascin-C was inhibited by approximately 30% in the presence of 0.1 mg/ml GRGDS peptide, and higher concentrations did not significantly alter adhesion levels (Fig. 2). To establish the sequence specificity of the RGD-mediated interaction, the effect of GRGDS peptide was compared with inactive GRFDS peptide. The GRFDS peptide had no effect (not shown), demonstrating that the RGD-mediated interaction of tenascin-C is specific.

Fig. 2. The effect of RGD peptide on the interaction between newborn SMCs and tenascin-C. 96-well plates were coated with either BSA (triangle ), tenascin-C (bullet ), or the recombinant 10th-type III repeat of fibronectin (black-down-triangle ) as described for Fig. 1. Newborn SMCs were detached, washed once in adhesion buffer, and added to various concentrations of the peptide GRGDS. Cells and peptides were then preincubated for 30 min before plating. Values shown are the mean ± S.E. of triplicate samples. Nonspecific binding to control wells coated with BSA was not subtracted from each value.

[View Larger Version of this Image (14K GIF file)]

Effect of Cations on the Interaction between SMCs and Tenascin C

To determine the role of cations in the interaction between SMCs and tenascin-C, the adhesion assay was performed in the presence of increasing concentrations of EDTA (Fig. 3). The intact fibronectin molecule and its recombinant subunit were used as a positive control. Newborn cells adhered well to tenascin-C, fibronectin, or the recombinant fragment in the absence of EDTA. The addition of 1 mM EDTA reduced adhesion of newborn cells to the intact fibronectin molecule or tenascin-C by 50%, and nearly complete inhibition of cell adhesion to all substrates was observed with 10 mM EDTA (Fig. 3). These data suggest that cations are essential for adhesion of newborn SMCs to tenascin-C.

Fig. 3. The effect of EDTA on the adhesion of newborn SMCs to tenascin-C. 96-well plates were coated with solutions containing intact fibronectin (black-triangle), the recombinant 10th-type III repeat of fibronectin (down-triangle), or tenascin-C (bullet ). Newborn SMCs were detached, washed once with adhesion buffer, added to various concentrations of EDTA, and plated. The number of attached cells was quantified by colorimeter. Values shown are from a representative experiment in which triplicates are plotted as mean ± S.E.

[View Larger Version of this Image (14K GIF file)]

The type of cation markedly affects the association rate constant of the ligand for integrin (18-21). To determine which cation influences adhesion of SMCs to tenascin-C, we examined the effect of both Ca2+ and Mg2+ cations on cell adhesion. The level of newborn SMC adhesion to tenascin-C or to the recombinant fibronectin fragment increased as the Mg2+ concentration increased (Fig. 4). Maximal cell adhesion to both substrates was observed in the range of 5-10 mM Mg2+. In contrast, Ca2+ was ineffective. Thus, we conclude that there is the potential for a 3-fold increase in the interaction between newborn SMCs and tenascin-C in the presence of Mg2+.

Fig. 4. The effect of Mg2+ and Ca2+ on the interaction of newborn cells with tenascin-C. 96-well plates were coated with either tenascin-C (black-square, Mg2+; square , Ca2+) or the recombinant 10th-type III repeat of fibronectin (bullet , Mg2+; open circle , Ca2+) as described for Fig. 1. Newborn SMCs were detached, washed once in the adhesion buffer, added to various concentrations of either Ca2+ or Mg2+, and plated. Values shown are from the mean ± S.D. of triplicate samples. Nonspecific binding to BSA-coated control wells was not subtracted and was 0.23 ± S.E.

[View Larger Version of this Image (19K GIF file)]

Since Ca2+ ion can reverse the Mg2+-dependent adhesion of some integrins, particularly alpha 2beta 1 (19), we examined its effect on the adhesion of newborn SMCs to tenascin-C in the presence of Mg2+ cation. We found no indication that the presence of Ca2+ up to 10 mM, a concentration that completely reversed the Mg2+-dependent adhesion of human fibroblasts (22), could inhibit the Mg2+-dependent adhesion of newborn cells (not shown).

Mapping of the Active Domain of Tenascin C

We next mapped the active domain of tenascin-C using recombinant proteins corresponding to full-length Fbg-L and FN-L domains as well as FN-L subdomains 6-8, A-D, A1A2, and D. The ability of these domains or subdomains to interact with newborn SMCs was determined by an adhesion assay. The level of adhesion to the intact tenascin-C molecule was high compared with the fibronectin (Fig. 5). Newborn cells adhered to the Fbg-L domain, and although the level of adhesion was slightly lower, it was comparable to the intact tenascin-C (Fig. 5). In contrast, SMCs did not adhere either to the entire FN-L domain or its recombinant subdomains (Fig. 5). As with the intact tenascin-C, the Fbg-L-adherent cells remained round and did not spread (not shown). Similar results were obtained with adult SMCs, although the level of adhesion to the Fbg-L domain was markedly lower (not shown).

Fig. 5. Mapping the active domain of tenascin-C. Microtiter plate was coated with BSA, fibronectin (FN), intact tenascin-C (TN), and the recombinant proteins corresponding to the Fbg-L domain (fbg), the entire FN-L repeats (All), the constitutively repeats 6-8, the alternatively spliced A-D, A1A2, and D domains. The adhesion assay was performed with newborn SMCs. Values shown are from a representative experiment in which triplicates are plotted ± S.E.

[View Larger Version of this Image (18K GIF file)]

The inability of FN-L domain or subdomains to promote cell adhesion could be explained by reduced capacity of the FN-L repeats to coat tissue culture dishes, by the loss of function as a result of binding to tissue culture dishes, or by the lack of activity of the FN-L domains. To distinguish between these possibilities, the recombinant FN-L proteins were labeled with 125I, and their ability to coat the tissue culture dishes was compared with the Fbg-L domain. We found no difference in the coating efficiency of these recombinant proteins (not shown). To determine whether binding to tissue culture dishes influenced the activity of the recombinant proteins, we examined the ability of soluble Fbg-L or FN-L domains and subdomains to inhibit the interaction between intact tenascin-C and SMCs. The soluble FN-L domain or subdomains were inactive, whereas 200 µg/ml soluble Fbg-L reduced adhesion of SMCs to tenascin-C by 70% (Fig. 6). The soluble recombinant Fbg-L had no effect on the adhesion of SMCs to either intact fibronectin or its recombinant fragment (Fig. 6). Further, adhesion of SMCs to the Fbg-L domain was controlled by the same factors that regulated adhesion of cells to tenascin-C, i.e. adhesion was completely inhibited by EDTA and promoted by Mg2+ cation but not Ca2+ (not shown). Taken together, these data led us to conclude that the Fbg-L domain, but not FN-L domain, mediates adhesion of SMCs to tenascin-C.

Fig. 6. Effect of the soluble tenascin-C domains on newborn SMC adhesion. 96-well plates were coated with fibronectin (FN), the recombinant 10th-type III repeat of fibronectin (10 III), or intact tenascin-C molecule (TN). Newborn SMCs were incubated for 15 min at 37 °C with a solution of 200 µg/ml recombinant Fbg-L domain (black), the entire FN-L domain (gray), or the alternatively spliced A-D repeats (laddered). Control cells had only BSA (unshaded). Adhesion was measured as described above. Values shown are from representative experiments in which triplicates are plotted ± S.E.

[View Larger Version of this Image (30K GIF file)]

Mapping of the Active Site of Fbg-L Domain

To map the active site of the Fbg-L domain, we designed nine synthetic peptides, each containing a sequence of 30 amino acids, which together constituted the entire isolated Fbg-L domain. Some degree of overlap was included to avoid the possibility of splitting the active site and thereby losing the activity (Fig. 7).

Fig. 7. Peptides I-IX represent the amino-terminal through carboxyl-terminal part of the Fbg-L domain. The overlapping sequences have been underlined.

[View Larger Version of this Image (42K GIF file)]

The ability of the synthetic peptides to directly interact with newborn cells were determined by an adhesion assay. Tissue culture plates were coated with increasing concentrations of peptides from 0.1 to 10 µg/ml, and adhesion of newborn cells was measured. Cell adhesion was promoted as peptide concentration was increased from 0.1 to 1 µg/ml (not shown). Adhesion reached saturation levels at 1 µg/ml, and no significant change was observed beyond 10 µg/ml; therefore, tissue culture plates were coated with a solution of 10 µg/ml of peptides in all subsequent experiments. As shown in Fig. 8A, peptide VIII was the only peptide capable of strongly promoting newborn cell adhesion when coated on the tissue culture dishes, and it accounted for most (80%) of the adhesion activity of the Fbg-L domain. Peptide IX exhibited 30% activity, and other peptides were inactive. As with the interaction with intact tenascin-C or the isolated Fbg-L domain, peptide VIII-adherent cells remained round. Further, as with the whole Fbg-L domain, adhesion to peptide VIII was blocked by EDTA and promoted by Mg2+ (not shown).

Fig. 8. A, the effect of peptides on the interaction between newborn SMCs and tenascin-C. 96-well plates were coated with solutions containing BSA (C), fibronectin (FN), tenascin-C (TN), Fbg-L, and synthetic peptides at a concentration of 10 µg/ml in phosphate-buffered saline. The adhesion assay was performed with newborn rat SMCs. Values shown are from a representative experiment in which triplicates are plotted as mean ± S.E. B, the effect of soluble peptides on the interaction between SMCs and intact tenascin-C or the recombinant fibrinogen-like domain. 96-well plates were coated with BSA, intact tenascin-C (TN), or Fbg-L, and adhesion of newborn cells was measured in the presence of 1 µM synthetic peptides.

[View Larger Version of this Image (31K GIF file)]

The inability of other peptides to promote SMCs adhesion suggests that peptide VIII was the only peptide that matched the active site of the Fbg-L domain. However, we cannot rule out the possibility that either other peptides did not bind to tissue culture dishes or that they lost their function as a result of binding to tissue culture dishes. We found no difference in the ability of peptides to coat tissue culture dishes (not shown). To determine whether peptides lose their function as a result of binding to tissue culture dishes, an adhesion assay was performed in the presence of soluble peptides. As shown in Fig. 8B, in addition to peptide VIII, soluble peptides III and VI completely blocked adhesion of newborn cells to either intact tenascin-C or the Fbg-L domain. Other peptides were either partially active (IX) or were completely inactive (I, IV, V). This suggests that peptide III or VI may lose their function as a result of conformational changes induced after binding to tissue culture dishes. If true, these peptides may represent a sensitive active site. It is thus unclear whether these sites remain active when soluble tenascin-C is incorporated into the insoluble extracellular matrix substrate.

To assess the specificity of adhesion to peptide VIII, we evaluated the ability of the soluble Fbg-L domain to inhibit SMC adhesion to peptide VIII. An adhesion assay was performed in the presence of increasing concentrations of soluble Fbg-L domain from 50-500 µg/ml. We found that 250 µg/ml soluble Fbg-L domain reduced adhesion of SMCs to the Fbg-L domain and peptide VIII by 70 and 80%, respectively. In contrast, the entire FN-L domain or the A1A2 subdomain had no effect (not shown).

We next mapped the active domain of tenascin-C that is involved in cell migration by determining the ability of the recombinant domains to block SMCs migration on tenascin-C substrate. As shown in Fig. 9, tenascin-C substrate stimulated SMC chemotaxis compared with BSA, and its level was comparable to the positive control, collagen. In the presence of Fbg-L domain or peptide VIII, SMC chemotaxis was inhibited by nearly 70%, whereas recombinant FN-L domain had no effect. This inhibitory activity is specific, because the Fbg-L domain or peptide VIII did not interfere with the migration of SMCs on collagen substrate (Fig. 9). We therefore conclude that the Fbg-L domain, but not the FN-L domain, mediates migration of SMCs on tenascin-C substrate, and most likely this occurs through the peptide VIII.

Fig. 9. The effect of peptide VIII on newborn cell migration. Cell migration was measured by a modification of Boyden's chamber. Polycarbonate filters were coated with BSA, tenascin-C (TN), or collagen (Col) substrates. Newborn rat SMCs were placed in the upper chamber, and BSA was placed in the lower chamber. In some experiments, cells were suspended in a solution of recombinant proteins corresponding to the entire FN-L domain (laddered), Fbg-L domain (black), or 1 µM peptide VIII (gray) before the addition to the upper chamber. Migrating cells were fixed and counted under a microscope. Nine high power fields (HPF) were counted for each triplicate. Values shown are from a representative experiment as mean ± S.E.

[View Larger Version of this Image (22K GIF file)]

DISCUSSION

We have identified the factors that control adhesion of SMCs to tenascin-C and mapped the active domain as well as the active site of the tenascin-C molecule. Based on these data, we propose that the adhesion of SMCs to tenascin-C is most likely mediated by integrin, which is different from other cell types. It is different from fibroblasts because heparin sulfate proteoglycans mediate adhesion of fibroblasts to tenascin-C (10). It is also different from endothelial cells, because adhesion of endothelial cells to tenascin-C is completely blocked by RGD peptide (9). In contrast, the adhesion of SMCs to tenascin-C is only partially (30%) blocked by RGD peptide. This suggests that at least two receptors, one of them RGD-dependent and the other RGD-independent, mediate the adhesion of SMCs to tenascin-C. Several lines of evidence suggest that these two receptors are most likely integrins, as the adhesion was 1) completely blocked by EDTA, 2) promoted by Mg2+ cation, but not Ca2+, and 3) completely blocked by the soluble Fbg-L domain or peptide VIII.

The cation-dependent adhesion of SMCs to tenascin-C may address some of the controversial issues related to the adhesion of cells to tenascin-C. Previous studies reported no cell adhesion to tenascin-C-coated culture dishes (23-26), whereas other reports showed a weak adhesion of cells (16, 27-31). In these reports, adhesion assays were performed with a buffer containing both Ca2+ and Mg2+. We observed that increasing Mg2+ concentrations increased SMCs adhesion, and maximal adhesion was achieved at 5-10 mM. In addition, the type of cations profoundly affects cell-integrin interaction, and in some cases, it is a deciding factor whether there is any adhesion at all. For example, the binding activity of alpha 2beta 1 integrins is promoted by Mg2+ cations, and Ca2+ reverses the effect of Mg2+ (19). This is particularly relevant to adhesion to tenascin-C, as it has been suggested that alpha 2beta 1 mediates the interaction of tenascin-C with endothelial cells (9, 32). Thus, the presence of Ca2+ cations in the adhesion buffer may negatively impact adhesion of some cell types to tenascin-C. Therefore, the concentration of cations and their type may at least partly explain the long controversy about cell-tenascin-C interaction.

Mg2+-mediated modulation may be relevant to the remodeling of the injured arteries after balloon angioplasty. Under normal physiological conditions, the extracellular environment has a higher concentration of Ca2+ than Mg2+ (33). In contrast, the intracellular Mg2+ concentration in a typical mammalian cell is between 15 and 30 mM, whereas intracellular Ca2+ is only about 1-2 µM (34-36). After balloon angioplasty, it is possible that a local increase in extracellular Mg2+ levels might occur as the damaged tissue releases its cellular content. It is conceivable that such an increase in the extracellular Mg2+ gradient, set up locally from the site of injury, along with growth factors released by the platelets at the injured site, could stimulate tenascin-C-SMC interaction possibly through an integrin receptor. This would then provide the stimulus and directional signaling necessary to mobilize SMCs.

The characterization of tenascin-C isoforms produced by adult and newborn SMCs and the expression of recombinant domains and subdomains allowed mapping of the active domain of tenascin-C. We have found that the Fbg-L domain accounts for nearly all of the adhesive activity of tenascin-C and that all the parameters that influence adhesion of SMCs to tenascin-C also equally affect interaction of SMCs with the Fbg-L domain. As we have shown, experimental artifacts cannot explain the lack of activity of the full-length FN-L domain, and the Fbg-L domain most likely represents an authentic active adhesive domain. This domain is located at the tip of the intact tenascin-C molecule and is easily accessible for interaction with cells. The Fbg-L domain is highly conserved among species, and compared with the other domain, it is the most conserved domain of tenascin-C. Erickson (37) has suggested that the other domains may act as a spacer for the Fbg-L domain. Since this domain is also involved in SMC migration, it suggests that the initial interaction of SMCs with the Fbg-L domain of tenascin-C is critical for cell chemotaxis.

We observed that peptide VIII could duplicate nearly all of the activity of the Fbg-L domain when coated onto tissue culture dishes. Since this peptide represents only about 1% intact tenascin-C polypeptide monomer, it suggests that the interaction between the cell surface receptor and this peptide is extremely specific. In addition, peptide VIII is highly conserved. There is 96% homology between peptide VIII of human and chicken, and the only mutation is the conservative substitution of Arg for Lys, which most likely does not affect peptide activity. Based on our findings, we hypothesize that this peptide represents the active site of the Fbg-L domain that mediates SMCs adhesion and migration.

Although the timing and location of expression during embryogenesis and its anti-adhesive activity suggest a potential role for tenascin-C in cell migration, no data directly supporting this idea have been previously reported. Our study directly shows that tenascin-C promotes cell migration, and the activity has been mapped to the peptide VIII of the Fbg-L domain. It has been suggested that the migration-promoting activity of tenascin-C may reside on the FN-L domain, specifically the alternatively spliced region, as this region down-regulated focal adhesion points of endothelial cells (38) and SMCs (39). Since down-regulation of focal adhesion points is a prerequisite for migration of adherent cells, it has been suggested that the alternatively spliced region may promote cell migration (38, 39). We found, however, that neither the FN-L domain or its subdomains, including the full-length alternatively spliced region, had neither adhesive- nor migration-promoting activities for detached SMCs and that the Fbg-L domain can account for nearly all of the activities. However, we cannot exclude the possibility that adherent SMCs may need the alternatively spliced region for cell detachment, because our migration assay was performed with detached SMCs. It is thus conceivable that the alternatively spliced region is needed to down-regulate focal adhesion points of adherent SMCs and to promote cell detachment. Once detached, however, the Fbg-L domain alone may be sufficient to maintain cell movement.

Tenascin C is largely expressed during embryonic development, but it is down-regulated in adult tissue (8). We found differences in the ability of newborn and adult SMCs to adhere to tenascin-C, which was consistent throughout multiple isolates and passages of adult and newborn cells. These data suggest that the newborn cells have a greater number of stable cell surface receptors for tenascin-C. In many circumstances, the basic cellular mechanisms that originally were used during embryonic development may be reactivated under pathological conditions. We have reported that formation of neointima during wound healing in the balloon-injured adult rat carotid artery is dependent on reexpression of developmentally regulated gene(s), and the reactivation of these genes may be responsible for the formation of neointima (40-44). The differential ability of the newborn and adult SMCs to adhere to tenascin-C suggests that the reexpression of a developmentally regulated gene like tenascin-C provides a suitable substratum for the subpopulation of aortic SMCs to migrate and form neointima.

In summary, we have characterized the parameters that determine the interaction between SMCs and tenascin-C. We have shown that the Fbg-L domain, but not the FN-L domain, is involved in SMC adhesion and migration. We further mapped the active site of the Fbg-L domain to a 30-amino acid peptide, peptide VIII, which is located near the carboxyl-terminal part of the domain. Based on these data, we hypothesize that the interaction between SMCs and the Fbg-L domain of tenascin-C is essential for cell adhesion and migration, and blocking this interaction may blunt SMC migration from media into the neointima and ultimately affect neointimal formation.

FOOTNOTES

*   Supported in part by National Institutes of Health Grant HL50566 (to B. G. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   To whom correspondence should be addressed: Cedar-Sinai Medical Center, Davis Bldg. 1016, 8700 Beverly Blvd., Los Angeles, CA 90048. Tel.: 310-855-7621; Fax: 310-652-8131; E-mail: sharifi{at}CSMC.edu.
1   The abbreviations used are: FN-L, fibronectin-type III repeats; Fbg-L, fibrinogen-like domain; SMC, smooth muscle cell; DMEM, Dulbecco's modified Eagle's medium; BSA, bovine serum albumin.

REFERENCES

  1. Bronner-Fraser, M., Stern, C. D., and Fraser, S. (1991) J. Craniofacial Genet. Dev. Biol. 11, 214-222 [Medline] [Order article via Infotrieve]
  2. Kaplony, A., Zimmermann, D. R., Fischer, R. W., Imhof, B. A., Odermatt, B. F., Winterhalter, K. H., and Vaughan, L. (1991) Development 112, 605-614 [Abstract]
  3. Epperlein, H. H., Halfter, W., and Tucker, R. P. (1988) Development 103, 743-756 [Abstract/Free Full Text]
  4. Mackie, E. J., Tucker, R. P., Halfter, W., Chiquet-Ehrismann, R., and Epperlein, H. H. (1988) Ann. N. Y. Acad. Sci. 540, 64-77
  5. Spence, S. G., and Poole, T. J. (1994) Int. J. Dev. Biol. 38, 85-98 [Medline] [Order article via Infotrieve]
  6. Deryugina, E. I., and Bourdon, M. A. (1996) J. Cell Sci. 109, 643-652 [Abstract/Free Full Text]
  7. Chung, C. Y., Murphy-Ullrich, J. E., and Erickson, H. P. (1996) Mol. Biol. Cell 7, 883-892 [Abstract]
  8. Erickson, H. P., and Bourdon, M. A. (1989) Annu. Rev. Cell Biol. 5, 71-92 [CrossRef]
  9. Joshi, P., Chung, C. Y., Aukhil, I., and Erickson, H. P. (1993) J. Cell Sci. 106, 389-400 [Abstract]
  10. Aukhil, I., Joshi, P., Yan, Y., and Erickson, H. P. (1993) J. Biol. Chem. 268, 2542-2553 [Abstract/Free Full Text]
  11. Sharifi, B. G., LaFleur, D. W., Pirola, C. J., Forrester, J. S., and Fagin, J. A. (1992) J. Biol. Chem. 267, 23910-23915 [Abstract/Free Full Text]
  12. LaFleur, D. W., Fagin, J. A., Forrester, J. S., Rubin, S. A., and Sharifi, B. G. (1994) J. Biol. Chem. 269, 20757-20763 [Abstract/Free Full Text]
  13. Lemire, J. M., Covin, C. W., White, S., Giachelli, C. M., and Schwartz, S. M. (1994) Am. J. Pathol. 144, 1068-1081 [Abstract]
  14. Liaw, L., Almeida, M., Hart, C. E., Schwartz, S. M., and Giachelli, C. M. (1994) Circ. Res. 74, 214-224 [Abstract/Free Full Text]
  15. Aufderheide, E., and Ekblom, P. (1988) J. Cell Biol. 107, 2341-2349 [Abstract/Free Full Text]
  16. Bourdon, M. A., and Ruoslahti, E. (1989) J. Cell Biol. 108, 1149-1155 [Abstract/Free Full Text]
  17. Hautanen, A., Gailit, J., Mann, D. M., and Ruoslahti, E. (1989) J. Biol. Chem. 264, 1437-1442 [Abstract/Free Full Text]
  18. Kirchhofer, D., Grzesiak, J., and Pierschbacher, M. D. (1991) J. Biol. Chem. 266, 4471-4477 [Abstract/Free Full Text]
  19. Kirchhofer, D., Languino, L. R., Ruoslahti, E., and Pierschbacher, M. D. (1990) J. Biol. Chem. 265, 615-618 [Abstract/Free Full Text]
  20. Smith, J. W., and Cheresh, D. A. (1991) J. Biol. Chem. 266, 11429-11432 [Abstract/Free Full Text]
  21. Gailit, J., and Ruoslahti, E. (1988) J. Biol. Chem. 263, 12927-12932 [Abstract/Free Full Text]
  22. Grzesiak, J. J., Davis, G. E., Kirchhofer, D., and Pierschbacher, M. D. (1992) J. Cell Biol. 117, 1109-1117 [Abstract/Free Full Text]
  23. Lotz, M. M., Burdsal, C. A., Erickson, H. P., and McClay, D. R. (1989) J. Cell Biol. 109, 1795-1805 [Abstract/Free Full Text]
  24. Lightner, V. A., and Erickson, H. P. (1990) J. Cell Sci. 95, 263-277 [Abstract/Free Full Text]
  25. Aukhil, I., Slemp, C. C., Lightner, V. A., Nishimura, K., Briscoe, G., and Erickson, H. P. (1990) Matrix 10, 98-111 [Medline] [Order article via Infotrieve]
  26. Saginati, M., Siri, A., Balza, E., Ponassi, M., and Zardi, L. (1992) Eur. J. Biochem. 205, 545-549 [Medline] [Order article via Infotrieve]
  27. Friedlander, D. R., Hoffman, S., and Edelman, G. M. (1988) J. Cell Biol. 107, 2329-2340 [Abstract/Free Full Text]
  28. Chiquet-Ehrismann, R., Kalla, P., Pearson, C. A., Beck, K., and Chiquet, M. (1988) Cell 53, 383-390 [CrossRef][Medline] [Order article via Infotrieve]
  29. Spring, J., Beck, K., and Chiquet-Ehrismann, R. (1989) Cell 59, 325-334 [CrossRef][Medline] [Order article via Infotrieve]
  30. Norenberg, U., Wille, H., Wolff, J. M., Frank, R., and Rathjen, F. G. (1992) Neuron 8, 849-863 [CrossRef][Medline] [Order article via Infotrieve]
  31. Prieto, A. L., Andersson-Fisone, C., and Crossin, K. L. (1992) J. Cell Biol. 119, 663-678 [Abstract/Free Full Text]
  32. Sriramarao, P., Mendler, M., and Bourdon, M. A. (1993) J. Cell Sci. 105, 1001-1012 [Abstract]
  33. Olinger, M. L. (1989) Emerg. Med. Clin. North Am. 7, 795-822 [Medline] [Order article via Infotrieve]
  34. Polimeni, P. I., and Page, E. (1973) Circ. Res. 33, 367-374 [Free Full Text]
  35. Henrotte, J. G. (1988) Magnesium 7, 306-314 [Medline] [Order article via Infotrieve]
  36. Caddell, J. L., and Reed, G. F. (1989) Magnesium 8, 65-70 [Medline] [Order article via Infotrieve]
  37. Erickson, H. P. (1994) Perspect. Dev. Neurobiol. 2, 9-19 [Medline] [Order article via Infotrieve]
  38. Murphy-Ullrich, J. E., Lightner, V. A., Aukhil, I., Yan, Y. Z., Erickson, H. P., and Hook, M. (1991) J. Cell Biol. 115, 1127-1136 [Abstract/Free Full Text]
  39. Hahn, A. W., Kern, F., Jonas, U., John, M., Buhler, F. R., and Resink, T. J. (1995) J. Vasc. Res. 32, 162-174 [Medline] [Order article via Infotrieve]
  40. Majesky, M. W., Giachelli, C. M., Reidy, M. A., and Schwartz, S. M. (1992) Circ. Res. 71, 759-768 [Abstract/Free Full Text]
  41. Schwartz, S. M., Reidy, M. R., and Clowes, A. (1985) Ann. N. Y. Acad. Sci. 454, 292-304 [Medline] [Order article via Infotrieve]
  42. Schwartz, S. M. (1994) Exp. Nephrol. 2, 63-77 [Medline] [Order article via Infotrieve]
  43. Schwartz, S. M., Majesky, M. W., and Murry, C. E. (1995) Atherosclerosis 118, (suppl.) 125-140
  44. Schwartz, S. M., deBlois, D., and O'Brien, E. R. (1995) Circ. Res. 77, 445-465 [Free Full Text]
Volume 272, Number 52, Issue of December 26, 1997 pp. 32798-32803
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
Y. Sawada, K. Onoda, K. Imanaka-Yoshida, J. Maruyama, K. Yamamoto, T. Yoshida, and H. Shimpo
Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis
Cardiovasc Res, June 1, 2007; 74(3): 366 - 376.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Tamaoki, K. Imanaka-Yoshida, K. Yokoyama, T. Nishioka, H. Inada, M. Hiroe, T. Sakakura, and T. Yoshida
Tenascin-C Regulates Recruitment of Myofibroblasts during Tissue Repair after Myocardial Injury
Am. J. Pathol., July 1, 2005; 167(1): 71 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
K. Yamamoto, K. Onoda, Y. Sawada, K. Fujinaga, K. Imanaka-Yoshida, H. Shimpo, T. Yoshida, and I. Yada
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice
Cardiovasc Res, February 15, 2005; 65(3): 737 - 742.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
K. Fujinaga, K. Onoda, K. Yamamoto, K. Imanaka-Yoshida, M. Takao, T. Shimono, H. Shimpo, T. Yoshida, and I. Yada
Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-c synthesis and smooth muscle cell proliferation in free artery grafts
J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 357 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
K. Wallner, C. Li, P. K. Shah, K.-J. Wu, S. M. Schwartz, and B. G. Sharifi
EGF-Like Domain of Tenascin-C Is Proapoptotic for Cultured Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1416 - 1421.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
M. Qin, Z. Zeng, J. Zheng, P. K. Shah, S. M. Schwartz, L. D. Adams, and B. G. Sharifi
Suppression Subtractive Hybridization Identifies Distinctive Expression Markers for Coronary and Internal Mammary Arteries
Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 425 - 433.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
J. S. Forrester
Prevention of Plaque Rupture: A New Paradigm of Therapy
Ann Intern Med, November 19, 2002; 137(10): 823 - 833.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Adams, J. L. Jones, R. A. Walker, J. H. Pringle, and S. C. Bell
Changes in Tenascin-C Isoform Expression in Invasive and Preinvasive Breast Disease
Cancer Res., June 1, 2002; 62(11): 3289 - 3297.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. Wallner, B. G. Sharifi, P. K. Shah, S. Noguchi, H. DeLeon, and J. N. Wilcox
Adventitial remodeling after angioplasty is associated with expression of tenascin mRNA by adventitial myofibroblasts
J. Am. Coll. Cardiol., February 1, 2001; 37(2): 655 - 661.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
K. Wallner, C. Li, M. C. Fishbein, P. K. Shah, and B. G. Sharifi
Arterialization of human vein grafts is associated with tenascin-C expression
J. Am. Coll. Cardiol., September 1, 1999; 34(3): 871 - 875.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
K. Wallner, C. Li, P. K. Shah, M. C. Fishbein, J. S. Forrester, S. Kaul, and B. G. Sharifi
Tenascin-C Is Expressed in Macrophage-Rich Human Coronary Atherosclerotic Plaque
Circulation, March 16, 1999; 99(10): 1284 - 1289.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Lauren, Y. Gunji, and K. Alitalo
Is Angiopoietin-2 Necessary for the Initiation of Tumor Angiogenesis?
Am. J. Pathol., November 1, 1998; 153(5): 1333 - 1339.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Yokoyama, H. P. Erickson, Y. Ikeda, and Y. Takada
Identification of Amino Acid Sequences in Fibrinogen gamma -Chain and Tenascin C C-terminal Domains Critical for Binding to Integrin alpha vbeta 3
J. Biol. Chem., May 26, 2000; 275(22): 16891 - 16898.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LaFleur, D. W.
Right arrow Articles by Sharifi, B. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LaFleur, D. W.
Right arrow Articles by Sharifi, B. G.
Social Bookmarking
Add to CiteULike